

RECEIVED  
CENTRAL FAX CENTER

001/004



JAN 16 2007

**FACSIMILE TRANSMITTAL**  
January 16, 2007

from **HOLLY D. KOZLOWSKI**  
Direct: 513-977-8568 / Fax: 513-977-8141 / [kozlowski@dinslaw.com](mailto:kozlowski@dinslaw.com)

To: Commissioner for Patents

Fax Number: 571-273-8300

Client Number: 25401-39

Pages:  
(including cover)

4

Comments:

If there are any problems in receiving this transmission, please call the fax room at (513) 977-8483 immediately. Thank you.

**Notice**

*This message is intended only for the use of the individuals or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this notice is not the intended recipient or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this notice in error, please notify us immediately by telephone and return these papers to us at the address below via first class mail.*

Cincinnati • 1900 Chemed Center • 255 East Fifth Street • Cincinnati, OH 45202 • Phone: (513) 977-8200

RECEIVED  
CENTRAL FAX CENTER

PATENT

JAN 16 2007

Docket No: 25401-39

**CERTIFICATE OF FACSIMILE**

I hereby certify that this paper is being transmitted via facsimile to: Mail Stop Amendment; Commissioner for Patents; P.O. Box 1450; Alexandria, VA 22313-1450 at facsimile number 571-273-8300 on January 16, 2007.

*Amis S. Rade*

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: Ulf Gyllensten et al : Paper No.  
Serial No.: 10/529,447 : Group Art Unit: 1637  
Filing Date: March 28, 2005 : Examiner: Thomas, David C.  
For: Method and Kit for Quantitative and Qualitative Determination of Human Papillomavirus

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Response in the above-identified application.

- ☐ Additional fee is required.  
☐ Also attached:  
The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUS PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	20	20	0	x 50 =	\$0.00
Independent Claims	2	2	0	x \$200 =	\$0.00
<b>TOTAL FEE DUE</b>					<b>\$0.00</b>

- [X] The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment, to Deposit Account No. 04-1133, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

By:

*Holly D. Kozlowski*

Holly D. Kozlowski  
Registration No. 30,468  
Attorney for Applicants  
DINSMORE & SHOHL LLP  
1900 Chemed Center  
255 East Fifth Street  
Cincinnati, Ohio 45202  
(513) 977-8568

1341921V1

**PATENT**

**Docket No: 25401-39**

**CERTIFICATE OF FACSIMILE**

**CERTIFICATE OF FACSIMILE**  
I hereby certify that this paper is being transmitted via  
facsimile to: Mail Stop Amendment; Commissioner  
for Patents; P.O. Box 1450; Alexandria, VA 22313-  
1450 at facsimile number 571-273-8300 on  
January 16, 2007.

January 16, 2007.  
Ronnie S. Dale  
IN THE UNITED STATES

**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant:	Ulf Gyllenstein et al	:	Paper No.	
Serial No.:	10/529,447	:	Group Art Unit:	1637
Filing Date:	March 28, 2005	:	Examiner:	Thomas, David C.
For:	<b>Method and Kit for Quantitative and Qualitative Determination of Human Papillomavirus</b>			

## **RESPONSE**

**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450**

Dear Sir:

Dear Sir:

In the Official Action dated December 14, 2006, the Examiner required restriction under 35 U.S.C. §§121 and 372 between Group I, claims 1-8 and 15-17 drawn to a method for quantitative and qualitative determination of human papillomavirus (HPV), and Group II, claims 9-14 and 13-20 drawn to a kit for detection and quantification of HPV.

Claims 9-14 and 18-20 drawn to a kit. This

Applicants elect the invention of Group II, claims 9-14 and 18-20 drawn to a kit. This election is made with traverse on the basis that it would not be unduly burdensome for the Examiner to examine all of claims 1-20 in the present application. Reconsideration is respectfully requested.

The Official Action also indicated that should Applicants elect Group II, Applicants are required to select one pair or primer sequences from Groups III-X (SEQ ID NOS. 1-8), one pair of primer sequences from Groups XI-XX (SEQ ID NOS. 9-18), one pair or probe sequences from Groups XXI-XXIV (SEQ ID NOS. 21-24), and one pair of probe sequences from Groups XXV-XXIX (SEQ ID NOS. 25-29). The Examiner asserted that the inventions listed in Groups III-X, XI-XX, XXI-XXIV, and XXV-XXIX do not relate to a single general inventive concept because they lack corresponding special technical features.


Application Serial No. 10/529,447  
Response filed January 16, 2007  
Official Action dated December 14, 2006

This election is traversed and reconsideration is respectfully requested. That is, independent claim 9 recites a kit for detection and quantification of HPV. The kit comprises the amplification primers of SEQ ID NOS. 1-8 and SEQ ID NOS. 21-24. Thus, all the amplification primers of SEQ ID NOS. 1-8 and all of the probes of SEQ ID NOS. 21-24 are required by claim 9. Thus, an election of any one pair of primer sequences and/or any one pair of probe sequences is inconsistent with the invention defined by claim 9. Since claim 9 does not recite these primers or probes as alternate embodiments, for example in a Markush group, the election requirement is not proper. Similarly, claim 9 optionally further requires the amplification primers of SEQ ID NOS. 9-18 and the probes of SEQ ID NOS. 25-29. Again, this optional embodiment of claim 9 requires all of the primers of SEQ ID NOS. 9-18 and all of the probes of SEQ ID NOS. 25-29. Election of any one pair of primers or probes is again inconsistent with the recited embodiment of the invention defined by claim 9. Accordingly, withdrawal of this election requirement is respectfully requested.

The undersigned telephoned the Examiner to discuss the withdrawal of this election requirement. The Examiner informed the undersigned that it was understood that all of the sequences of the respective groups III-X and XI-XX are required by claim 9 and that an election was required only to facilitate searching of the invention. To provide a complete response to the Official Action, therefore, Applicants elect the primer pair of SEQ ID NOS. 1 and 2, the probe of SEQ ID NO. 21, the primer pair of SEQ ID NOS. 9 and 10 and the probe of SEQ ID NO. 25. This election is only made for the present response to be considered as fully responsive, as an election among required primer sequences and probe sequences is, as discussed above, inappropriate.

Examination on the merits is requested.

Respectfully submitted,

  
Holly D. Kozlowski, Reg. No. 30,468  
Dinsmore & Shohl LLP  
1900 Chemed Center  
255 East Fifth Street  
Cincinnati, Ohio 45202  
(513) 977-8568

1341907v1